Walleye Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Walleye Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,900	Closed	-$98.2K	–	5153
2026 Q1	$98.2K	Buy	+1,900	New	+$96.8K	﹤0.01%	3682

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Walleye Capital's SUPN Position: Q2 2026 in Review

Walleye Capital sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 11,214 shares — an estimated $580K sold.

Walleye Capital first reported a position in SUPN in Q1 2022 and held it in 5 quarters. The position peaked at $1.64M in Q1 2022. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Walleye Capital reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 11,214 Supernus Pharmaceuticals shares in Q2 2026, an estimated $580K.
Walleye Capital first reported a position in Supernus Pharmaceuticals in Q1 2022 and held it in 5 quarters.
Walleye Capital's Supernus Pharmaceuticals position peaked at $1.64M in Q1 2022.
334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.